Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
Titel:
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
Auteur:
Parisi, Alessandro Porzio, Giampiero Cannita, Katia Venditti, Olga Avallone, Antonio Filippi, Roberto Salvatore, Lisa Tortora, Giampaolo Ribelli, Marta Nigro, Olga Gelsomino, Fabio Spallanzani, Andrea Zurlo, Valeria Leo, Silvana Dell'Aquila, Emanuela Claudia, Fulgenzi Lombardi, Pasquale Keränen, Susana Roselló Aimar, Giacomo Depetris, Ilaria Giampieri, Riccardo Morelli, Cristina De Tursi, Michele Tinari, Nicola Di Pietro, Francesca Romana De Galitiis, Federica Zanaletti, Nicoletta Troiani, Teresa Vitale, Pasquale Garajova, Ingrid Ghidini, Michele Spinelli, Gian Paolo Zoratto, Federica Roberto, Michela Ierino, Debora Petrillo, Angelica D'Orazio, Carla Ficorella, Corrado Cortellini, Alessio